Insider Buying: OraSure Technologies, Inc. (NASDAQ:OSUR) Director Purchases 47,659 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director John P. Kenny purchased 47,659 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $3.17 per share, with a total value of $151,079.03. Following the completion of the purchase, the director now owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. This represents a 204.93 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

OraSure Technologies Stock Performance

Shares of NASDAQ:OSUR opened at $3.13 on Friday. OraSure Technologies, Inc. has a 52-week low of $2.68 and a 52-week high of $8.04. The company has a market capitalization of $233.48 million, a P/E ratio of 20.87 and a beta of 0.05. The company has a 50-day simple moving average of $3.78 and a 200 day simple moving average of $4.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 5,234 shares during the period. Causeway Capital Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter valued at about $36,000. Raymond James Financial Inc. bought a new position in shares of OraSure Technologies in the fourth quarter valued at about $37,000. Boothbay Fund Management LLC acquired a new stake in shares of OraSure Technologies during the 4th quarter worth about $42,000. Finally, Gotham Asset Management LLC bought a new stake in shares of OraSure Technologies during the 4th quarter worth about $43,000. 93.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, February 22nd.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.